iMDK

Research use only, not for human use.

iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.

iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.(In Vitro):Administration of iMDK (50-500 nM) for 72 h quarterhydrate suppressed AKT phosphorylation in H441 lung adenocarcinoma cells after treatment dose-dependently. In contrast, iMDK quarterhydrate robustly increases p-ERK.(In Vivo):Intraperitoneally injection with 100 μl of iMDK ( (9 mg/kg/day) and ; oral administion of PD0325901 (5 mg/kg) effectively reduced lung tumor growth in a xenograft mouse model.

——

PI3K/Akt/mTOR signaling

PI3K

TRPV1

——

——

881970-80-5

376.4

C21H13FN2O2S

>98% (HPLC)

——

Fc1ccc(Cc2cn3cc(nc3s2)-c2cc3ccccc3oc2=O)cc1

——

(-20℃)

With Ice Pack

≥ 2 years